Selected research
Industry Growth & Trends
Global Opioids Agonist Drugs Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Opioids Agonist Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Opioids Agonist Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Opioids Agonist Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Opioids Agonist Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Opioids Agonist Drugs market include Janssen Pharmaceuticals, Inc, Sun Pharmaceuticals, Sanofi, Johnson & Johnson Services, Inc., Pfizer Inc, AbbVie Inc., Titan pharmaceuticals, Purdue Pharma and Mallinckrodt Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Opioids Agonist Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Opioids Agonist Drugs market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Opioids Agonist Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Opioids Agonist Drugs.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Opioids Agonist Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Opioids Agonist Drugs Market by Company
Janssen Pharmaceuticals, Inc
Sun Pharmaceuticals
Sanofi
Johnson & Johnson Services, Inc.
Pfizer Inc
AbbVie Inc.
Titan pharmaceuticals
Purdue Pharma
Mallinckrodt Pharmaceuticals
Hikma Pharmaceuticals PLC
Grünenthal
Endo Pharmaceuticals Inc.
Egalet Corporation
Boehringer Ingelheim
Allergan, Plc
Opioids Agonist Drugs Segment by Type
Fentanyl
Codeine
Morphine
Methadone
Meperidine
Hydrocodone
Opioids Agonist Drugs Segment by Application
Pain Management
Cough Treatment
Diarrhea Treatment
Opioids Agonist Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioids Agonist Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Opioids Agonist Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioids Agonist Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Opioids Agonist Drugs companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Fentanyl
- Codeine
- Morphine
- Methadone
- Meperidine
- Hydrocodone
Applications
- Pain Management
- Cough Treatment
- Diarrhea Treatment
Companies covered
- Janssen Pharmaceuticals, Inc
- Sun Pharmaceuticals
- Sanofi
- Johnson & Johnson Services, Inc.
- Pfizer Inc
- AbbVie Inc.
- Titan pharmaceuticals
- Purdue Pharma
- Mallinckrodt Pharmaceuticals
- Hikma Pharmaceuticals PLC
- Grünenthal
- Endo Pharmaceuticals Inc.
- Egalet Corporation
- Boehringer Ingelheim
- Allergan, Plc
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Opioids Agonist Drugs Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Opioids Agonist Drugs Market Size by Region (2021-2032)
- 1.4.1 Global Opioids Agonist Drugs Market Size by Region (2021-2026)
- 1.4.2 Global Opioids Agonist Drugs Market Size by Region (2027-2032)
- 1.5 Key Regions Opioids Agonist Drugs Market Size (2021-2032)
- 1.5.1 North America Opioids Agonist Drugs Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Opioids Agonist Drugs Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Opioids Agonist Drugs Market Size Growth Rate (2021-2032)
- 1.5.4 South America Opioids Agonist Drugs Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Opioids Agonist Drugs Market Size Growth Rate (2021-2032)
2 Opioids Agonist Drugs Market by Type
- 2.1 Type Introduction
- 2.1.1 Fentanyl
- 2.1.2 Codeine
- 2.1.3 Morphine
- 2.1.4 Methadone
- 2.1.5 Meperidine
- 2.1.6 Hydrocodone
- 2.2 Global Opioids Agonist Drugs Market Size by Type
- 2.2.1 Global Opioids Agonist Drugs Market Size Overview by Type (2021-2032)
- 2.2.2 Global Opioids Agonist Drugs Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Opioids Agonist Drugs Market Size Forecasted by Type (2027-2032)
- 2.3 Global Opioids Agonist Drugs Market Size by Regions
- 2.3.1 North America Opioids Agonist Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Opioids Agonist Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Opioids Agonist Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Opioids Agonist Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Opioids Agonist Drugs Market Size Breakdown by Type (2021-2026)
3 Opioids Agonist Drugs Market by Application
- 3.1 Type Introduction
- 3.1.1 Pain Management
- 3.1.2 Cough Treatment
- 3.1.3 Diarrhea Treatment
- 3.2 Global Opioids Agonist Drugs Market Size by Application
- 3.2.1 Global Opioids Agonist Drugs Market Size Overview by Application (2021-2032)
- 3.2.2 Global Opioids Agonist Drugs Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Opioids Agonist Drugs Market Size Forecasted by Application (2027-2032)
- 3.3 Global Opioids Agonist Drugs Market Size by Regions
- 3.3.1 North America Opioids Agonist Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Opioids Agonist Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Opioids Agonist Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Opioids Agonist Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Opioids Agonist Drugs Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Opioids Agonist Drugs Industry Trends
- 4.2 Opioids Agonist Drugs Industry Drivers
- 4.3 Opioids Agonist Drugs Industry Opportunities and Challenges
- 4.4 Opioids Agonist Drugs Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Opioids Agonist Drugs Revenue (2021-2026)
- 5.2 Global Opioids Agonist Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Opioids Agonist Drugs Key Company Headquarters & Area Served
- 5.4 Global Opioids Agonist Drugs Company, Product Type & Application
- 5.5 Global Opioids Agonist Drugs Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Opioids Agonist Drugs Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Opioids Agonist Drugs Players Market Share by Revenue in 2025
- 5.6.3 2025 Opioids Agonist Drugs Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Janssen Pharmaceuticals, Inc
- 6.1.1 Janssen Pharmaceuticals, Inc Company Information
- 6.1.2 Janssen Pharmaceuticals, Inc Business Overview
- 6.1.3 Janssen Pharmaceuticals, Inc Opioids Agonist Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Janssen Pharmaceuticals, Inc Opioids Agonist Drugs Product Portfolio
- 6.1.5 Janssen Pharmaceuticals, Inc Recent Developments
- 6.2 Sun Pharmaceuticals
- 6.2.1 Sun Pharmaceuticals Company Information
- 6.2.2 Sun Pharmaceuticals Business Overview
- 6.2.3 Sun Pharmaceuticals Opioids Agonist Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Sun Pharmaceuticals Opioids Agonist Drugs Product Portfolio
- 6.2.5 Sun Pharmaceuticals Recent Developments
- 6.3 Sanofi
- 6.3.1 Sanofi Company Information
- 6.3.2 Sanofi Business Overview
- 6.3.3 Sanofi Opioids Agonist Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Sanofi Opioids Agonist Drugs Product Portfolio
- 6.3.5 Sanofi Recent Developments
- 6.4 Johnson & Johnson Services, Inc.
- 6.4.1 Johnson & Johnson Services, Inc. Company Information
- 6.4.2 Johnson & Johnson Services, Inc. Business Overview
- 6.4.3 Johnson & Johnson Services, Inc. Opioids Agonist Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Johnson & Johnson Services, Inc. Opioids Agonist Drugs Product Portfolio
- 6.4.5 Johnson & Johnson Services, Inc. Recent Developments
- 6.5 Pfizer Inc
- 6.5.1 Pfizer Inc Company Information
- 6.5.2 Pfizer Inc Business Overview
- 6.5.3 Pfizer Inc Opioids Agonist Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Pfizer Inc Opioids Agonist Drugs Product Portfolio
- 6.5.5 Pfizer Inc Recent Developments
- 6.6 AbbVie Inc.
- 6.6.1 AbbVie Inc. Company Information
- 6.6.2 AbbVie Inc. Business Overview
- 6.6.3 AbbVie Inc. Opioids Agonist Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 AbbVie Inc. Opioids Agonist Drugs Product Portfolio
- 6.6.5 AbbVie Inc. Recent Developments
- 6.7 Titan pharmaceuticals
- 6.7.1 Titan pharmaceuticals Company Information
- 6.7.2 Titan pharmaceuticals Business Overview
- 6.7.3 Titan pharmaceuticals Opioids Agonist Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Titan pharmaceuticals Opioids Agonist Drugs Product Portfolio
- 6.7.5 Titan pharmaceuticals Recent Developments
- 6.8 Purdue Pharma
- 6.8.1 Purdue Pharma Company Information
- 6.8.2 Purdue Pharma Business Overview
- 6.8.3 Purdue Pharma Opioids Agonist Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Purdue Pharma Opioids Agonist Drugs Product Portfolio
- 6.8.5 Purdue Pharma Recent Developments
- 6.9 Mallinckrodt Pharmaceuticals
- 6.9.1 Mallinckrodt Pharmaceuticals Company Information
- 6.9.2 Mallinckrodt Pharmaceuticals Business Overview
- 6.9.3 Mallinckrodt Pharmaceuticals Opioids Agonist Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Mallinckrodt Pharmaceuticals Opioids Agonist Drugs Product Portfolio
- 6.9.5 Mallinckrodt Pharmaceuticals Recent Developments
- 6.10 Hikma Pharmaceuticals PLC
- 6.10.1 Hikma Pharmaceuticals PLC Company Information
- 6.10.2 Hikma Pharmaceuticals PLC Business Overview
- 6.10.3 Hikma Pharmaceuticals PLC Opioids Agonist Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Hikma Pharmaceuticals PLC Opioids Agonist Drugs Product Portfolio
- 6.10.5 Hikma Pharmaceuticals PLC Recent Developments
- 6.11 Grünenthal
- 6.11.1 Grünenthal Company Information
- 6.11.2 Grünenthal Business Overview
- 6.11.3 Grünenthal Opioids Agonist Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Grünenthal Opioids Agonist Drugs Product Portfolio
- 6.11.5 Grünenthal Recent Developments
- 6.12 Endo Pharmaceuticals Inc.
- 6.12.1 Endo Pharmaceuticals Inc. Company Information
- 6.12.2 Endo Pharmaceuticals Inc. Business Overview
- 6.12.3 Endo Pharmaceuticals Inc. Opioids Agonist Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Endo Pharmaceuticals Inc. Opioids Agonist Drugs Product Portfolio
- 6.12.5 Endo Pharmaceuticals Inc. Recent Developments
- 6.13 Egalet Corporation
- 6.13.1 Egalet Corporation Company Information
- 6.13.2 Egalet Corporation Business Overview
- 6.13.3 Egalet Corporation Opioids Agonist Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Egalet Corporation Opioids Agonist Drugs Product Portfolio
- 6.13.5 Egalet Corporation Recent Developments
- 6.14 Boehringer Ingelheim
- 6.14.1 Boehringer Ingelheim Company Information
- 6.14.2 Boehringer Ingelheim Business Overview
- 6.14.3 Boehringer Ingelheim Opioids Agonist Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Boehringer Ingelheim Opioids Agonist Drugs Product Portfolio
- 6.14.5 Boehringer Ingelheim Recent Developments
- 6.15 Allergan, Plc
- 6.15.1 Allergan, Plc Company Information
- 6.15.2 Allergan, Plc Business Overview
- 6.15.3 Allergan, Plc Opioids Agonist Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.15.4 Allergan, Plc Opioids Agonist Drugs Product Portfolio
- 6.15.5 Allergan, Plc Recent Developments
7 North America
- 7.1 North America Opioids Agonist Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Opioids Agonist Drugs Market Size by Country (2021-2026)
- 7.3 North America Opioids Agonist Drugs Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Opioids Agonist Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Opioids Agonist Drugs Market Size by Country (2021-2026)
- 8.3 Europe Opioids Agonist Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Opioids Agonist Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Opioids Agonist Drugs Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Opioids Agonist Drugs Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Opioids Agonist Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Opioids Agonist Drugs Market Size by Country (2021-2026)
- 10.3 South America Opioids Agonist Drugs Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Opioids Agonist Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Opioids Agonist Drugs Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Opioids Agonist Drugs Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst